Stock Ratings / Health Care / NRSN / earnings

MDCX (35) DRMA (43) ENLV (35) XTLB (47) ⌘ Pro Terminal →

NeuroSense Therapeutics Ltd. (NRSN) Next Earnings Date & Expected ±12.5% Move

Q: When is NRSN's next earnings date?

Based on SEC filing cadence, NeuroSense Therapeutics Ltd. (NRSN)'s next quarterly reporting window is estimated around Dec 30, 2026.

Q: How much is NRSN stock expected to move on earnings?

Volatility modeling currently projects a ±12.5% event move for NRSN, spanning a range between $1.86 and $2.4.

$2.13 -9.75% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)

NeuroSense Therapeutics Ltd. (NRSN) carries a Roarable Rating of D- (Sell) with 38/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D- • RED ALERT Cap $4.0M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

RQD QUANT TACHOMETERRED ALERT • D-

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D

Each axis scored 0–20

12M PRICE TARGET CONE-8.9% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for NRSN)Realized 20D OHLCV Swing Band: ±12.5%

NEXT EST. WINDOW: Dec 30, 2026 (~58 DAYS)

Historical OHLCV Volatility ±12.5% Swing Band

±$0.27 Expected Swing

MODEL EARNINGS SETUP GAUGE

NRSN Quantitative Pre-Earnings Setup: 38/100

Trailing EPS: $4.25 • YoY Revenue Growth: 12.4%

Model Bullish Setup (38/100)Model Risk Weight (62/100)

Derived deterministically from RQD cash-flow quality, SEC accrual safety, and institutional flow (not a community poll).

LOG YOUR PERSONAL PRE-EARNINGS STANCE (SAVED LOCALLY IN BROWSER):

Recent SEC Reported Revenue, Net Profit & Diluted EPS Cadence

Period	Filed	Revenue	Net Profit	Free Cash Flow	Gross Margin
FY 2025	2025-12-31	$0	-$11.1M	-$7.7M	52%
FY 2024	2024-12-31	$0	-$10.2M	-$10.1M	52%
FY 2023	2023-12-31	$0	-$10.1M	-$8.4M	52%

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring NRSN)

✓Walkthrough of NRSN's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

NRSN // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -87.03%▼ DESCENDING CHANNEL

2026-10-30O $2.20H $2.22L $1.99C $2.13VOL 20.2K

RES: $3.63SUP: $-2.81SMA50: $5.44SMA200: $12.87

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

NRSN Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 NRSN Butterfly Map → + Track NRSN →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on NRSN today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for NRSN. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for NRSN today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (NRSN)

Health Care Rank #734 of 1016 ⚔️ MDCX vs NRSN Full Matrix →

1. Head-to-Head Health Care Peer Comparison (NRSN vs. MDCX, DRMA, ENLV, XTLB)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, NeuroSense Therapeutics Ltd. (NRSN) ranks #734 by composite RQD confidence (38/100, grade D-) and #960 by equity capitalization ($4.0M). Within this direct 5-issuer industry benchmark cohort, NRSN leads on earnings valuation at N/A trailing P/E, while ENLV leads on capital efficiency and profitability with -0.6% ROIC and — gross margin. XTLB currently holds the highest overall quantitative score in the immediate peer group at 47/100 (D) compared with NRSN at 38/100 (D-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
NRSN ACTIVE NeuroSense Therapeutics Ltd.	D-	38/100	—	—	-35.0%	-9.75%	$4.0M	Benchmark Subject
MDCX Medicus Pharma Ltd.	D-	35/100	—	—	-35.0%	-13.31%	$4.1M	/mdcx-vs-nrsn →
DRMA Dermata Therapeutics Inc.	D-	43/100	—	—	-35.0%	-3.84%	$4.2M	/drma-vs-nrsn →
ENLV Enlivex Ltd.	D-	35/100	—	—	-0.6%	-2.68%	$3.9M	/enlv-vs-nrsn →
XTLB XTL Biopharmaceuticals Ltd.	D	47/100	—	—	—	-12.44%	$4.3M	/xtlb-vs-nrsn →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001875091

In its most recent audited fiscal period (FY2025, filed 2025-12-31), NeuroSense Therapeutics Ltd. (NRSN) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$11.1M, operating cash flow of -$7.7M, and free cash flow of -$7.7M (+24.3% YoY). On the balance sheet, NRSN closed FY2025 with $1.0M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 1/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$0	-$11.1M	-$7.7M	-$7.7M	$1.0M	—
FY2024 (FY)	2024-12-31	$0	-$10.2M	-$10.1M	-$10.1M	$4.6M	—
FY2023 (FY)	2023-12-31	$0	-$10.1M	-$8.4M	-$8.4M	—	—

3. NRSN Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is NRSN stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 38/100 at a spot price of $2.13 (-9.75% 1D, market cap $4.0M). Pillar breakdown: Fundamental Cash Engine 9/20, Institutional 13F & Options Flow 4/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, NRSN ranks #734 in composite RQD confidence.

How does NRSN compare to MDCX and DRMA in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), NRSN carries a Roarable D- (38/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, MDCX (Medicus Pharma Ltd.) holds a D- grade (35/100 RQD, P/E N/A, ROIC -35.0%, cap $4.1M) and DRMA (Dermata Therapeutics Inc.) posts a D- grade (43/100 RQD, P/E N/A, ROIC -35.0%, cap $4.2M). Among the 5-stock peer group, NRSN leads on earnings multiple (N/A) while ENLV leads on capital efficiency (-0.6% ROIC).

What are the biggest fundamental strengths and SEC risk factors for NRSN?

Per NRSN's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001875091), NeuroSense Therapeutics Ltd. generated $0 in revenue, -$11.1M in net income, and -$7.7M in free cash flow against $1.0M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is NRSN trading relative to its 50-day, 200-day, and 52-week technical levels?

NRSN last traded at $2.13 (-9.75% on volume of 20,578 shares), positioning the stock -60.85% below its 50-day simple moving average ($5.44) and -83.45% below its 200-day simple moving average ($12.87). Across its 52-week range of $1.99 to $25.40, NRSN sits at the 0.6% percentile with a 14-day RSI of 21.6 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($1.86 to $2.40).

NRSN Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

When is NRSN's next earnings date?

Based on SEC filing cadence, NeuroSense Therapeutics Ltd. (NRSN)'s next quarterly reporting window is estimated around Dec 30, 2026.

How much is NRSN stock expected to move on earnings?

Volatility modeling currently projects a ±12.5% event move for NRSN, spanning a range between $1.86 and $2.4.

Direct Sub-Reports: NRSN RQD Cockpit NRSN 12M Forecast NRSN Earnings & Move NRSN Dividends & DRIP NRSN Insiders & 13F NRSN Whale Options NRSN Profit Sankey NRSN News & Why